Jan Basile to Humans
This is a "connection" page, showing publications Jan Basile has written about Humans.
Connection Strength
0.825
-
How We Got Where We Are in Blood Pressure Targets. Curr Hypertens Rep. 2021 06 10; 23(6):33.
Score: 0.030
-
A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. Hosp Pract (1995). 2016; 44(1):9-20.
Score: 0.021
-
Ambulatory blood pressure monitoring to diagnose hypertension--an idea whose time has come. J Am Soc Hypertens. 2016 Feb; 10(2):89-91.
Score: 0.021
-
ASH 2015 Annual Primary Care Program: What you missed by not attending. J Am Soc Hypertens. 2015 Nov; 9(11):831-6.
Score: 0.020
-
Recent clinical trials. J Am Soc Hypertens. 2014 Oct; 8(10):770-4; quiz 775-6.
Score: 0.019
-
Analysis of recent papers in hypertension treatment of hypertension in the setting of acute intracerebral hemorrhage: still no clear answer on the best BP level to intervene or what BP goal to achieve. J Clin Hypertens (Greenwich). 2014 Jan; 16(1):1-3.
Score: 0.018
-
Review of recent literature in hypertension: updated clinical practice guidelines for chronic kidney disease now include albuminuria in the classification system. J Clin Hypertens (Greenwich). 2013 Dec; 15(12):865-7.
Score: 0.018
-
Determining the relative antihypertensive potency and relative cardiovascular risk reduction associated with different thiazide and thiazide-type diuretics. J Clin Hypertens (Greenwich). 2013 Jun; 15(6):359-61.
Score: 0.017
-
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications. 2013 May-Jun; 27(3):280-6.
Score: 0.017
-
Analysis of recent papers in hypertension: nighttime administration of at least one antihypertensive medication is associated with better blood pressure control and cardiovascular outcomes in patients with type 2 diabetes or chronic kidney disease. J Clin Hypertens (Greenwich). 2013 Jan; 15(1):2-4.
Score: 0.017
-
The Rheos Pivotol trial evaluating baroreflex activation therapy fails to meet efficacy and safety end points in resistant hypertension: back to the drawing board. J Clin Hypertens (Greenwich). 2012 Mar; 14(3):184-6.
Score: 0.016
-
UK guidelines call for routine 24-hour ambulatory blood pressure monitoring in all patients to make the diagnosis of hypertension--not ready for prime time in the United States. J Clin Hypertens (Greenwich). 2011 Dec; 13(12):871-2.
Score: 0.016
-
New British guidelines mandate ambulatory blood pressure monitoring to diagnose hypertension in all patients: not ready for prime time in the United States. J Clin Hypertens (Greenwich). 2011 Nov; 13(11):785-6.
Score: 0.015
-
A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition. Postgrad Med. 2011 Jul; 123(4):38-45.
Score: 0.015
-
Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study. J Clin Hypertens (Greenwich). 2011 Mar; 13(3):162-9.
Score: 0.015
-
Treating the black hypertensive in 2010: achieve lower targets while awaiting more definitive evidence. J Clin Hypertens (Greenwich). 2011 Jan; 13(1):1-4.
Score: 0.015
-
Meta-analysis concludes angiotensin receptor blocker use increases the risk of developing cancer: concerns about the science and the message. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):661-3.
Score: 0.014
-
Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone. J Clin Hypertens (Greenwich). 2010 Oct; 12(10):809-12.
Score: 0.014
-
Review of recent literature: Existing kidney disease classification guideline needs to incorporate degree of proteinuria with estimated glomerular filtration rate to more accurately predict cardiovascular and renal risk. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):627-30.
Score: 0.014
-
One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk. Am J Med. 2010 Jul; 123(7 Suppl 1):S9-15.
Score: 0.014
-
Is there accord in ACCORD? Lower blood pressure targets in type 2 diabetes does not lead to fewer cardiovascular events except for reductions in stroke. J Clin Hypertens (Greenwich). 2010 Jul 01; 12(7):472-7.
Score: 0.014
-
Identifying and managing factors that interfere with or worsen blood pressure control. Postgrad Med. 2010 Mar; 122(2):35-48.
Score: 0.014
-
Largest meta-analysis to date suggests that patients at risk for cardiovascular disease events derive benefit from antihypertensive therapy regardless of baseline blood pressure and to reduce vascular events, lowering blood pressure is more important than choice of antihypertensive drug class. J Clin Hypertens (Greenwich). 2009 Dec; 11(12):743-5.
Score: 0.014
-
Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. South Med J. 2009 Oct; 102(10 Suppl):S1-S12.
Score: 0.013
-
Lessons learned from the ONTARGET and TRANSCEND trials. Curr Atheroscler Rep. 2009 Sep; 11(5):371-6.
Score: 0.013
-
Analysis of recent papers in hypertension. J Clin Hypertens (Greenwich). 2009 Apr; 11(4):238-40.
Score: 0.013
-
Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Int J Clin Pract. 2009 Apr; 63(4):656-66.
Score: 0.013
-
All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective. J Clin Hypertens (Greenwich). 2009 Jan; 11(1):5-10.
Score: 0.013
-
Rationale for fixed-dose combination therapy to reach lower blood pressure goals. South Med J. 2008 Sep; 101(9):918-24.
Score: 0.012
-
Shifting paradigms in defining and treating hypertension: addressing global risk with combination therapy. J Clin Hypertens (Greenwich). 2008 Jan; 10(1 Suppl 1):2-3.
Score: 0.012
-
Clinical considerations and practical recommendations for the primary care practitioner in the management of anemia of chronic kidney disease. South Med J. 2007 Dec; 100(12):1200-7.
Score: 0.012
-
Recognizing the link between CKD and CVD in the primary care setting: accurate and early diagnosis for timely and appropriate intervention. South Med J. 2007 May; 100(5):499-505.
Score: 0.011
-
Analysis of recent papers in hypertension. J Clin Hypertens (Greenwich). 2007 May; 9(5):396.
Score: 0.011
-
Fixed-dose combination therapy in the treatment of hypertension: ready for prime time. South Med J. 2007 Apr; 100(4):343-4.
Score: 0.011
-
A historical look at hypertension: celebrating 100 years with the Southern Medical Association. South Med J. 2006 Dec; 99(12):1412-3.
Score: 0.011
-
Management of global risk across the continuum of hypertensive heart disease. J Clin Hypertens (Greenwich). 2006 Aug; 8(8 Suppl 2):21-30; quiz 39-40.
Score: 0.011
-
The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens. 2006 Mar; 20(3):169-75.
Score: 0.010
-
Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction. J Cardiometab Syndr. 2006; 1(5):358-61.
Score: 0.010
-
The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich). 2004 Nov; 6(11):621-29; quiz 630-1.
Score: 0.010
-
Hypertension curriculum review. The importance of systolic blood pressure elevation in elderly persons. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):461-5.
Score: 0.009
-
Analysis of recent papers in hypertension. J Clin Hypertens (Greenwich). 2004 Feb; 6(2):96-101.
Score: 0.009
-
A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens (Greenwich). 2004 Jan; 6(1):18-25.
Score: 0.009
-
Beta-blockers for treatment of hypertension. Postgrad Med. 2003 Dec; 114(6 Suppl Role):11-7.
Score: 0.009
-
Beta-blockers for preventing sudden cardiac death. Postgrad Med. 2003 Dec; 114(6 Suppl Role):30-4.
Score: 0.009
-
Controlling blood pressure in 50% of all hypertensive patients: an achievable goal in the healthy people 2010 report? J Investig Med. 2003 Nov; 51(6):373-85.
Score: 0.009
-
Optimizing antihypertensive treatment in clinical practice. Am J Hypertens. 2003 Sep; 16(9 Pt 2):13S-17S.
Score: 0.009
-
Analysis of recent papers in hypertension. Need for more aggressive blood pressure control in diabetes. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):352-3.
Score: 0.009
-
Titration of beta-blockers in heart failure. How to maximize benefit while minimizing adverse events. Postgrad Med. 2003 Mar; 113(3):63-70; quiz 3.
Score: 0.009
-
Systolic blood pressure elevation: it's where the action is. Drugs Aging. 2003; 20(4):287-8.
Score: 0.008
-
American Society of Hypertension regional chapters: leveraging the impact of the clinical hypertension specialist in the local community. Am J Hypertens. 2002 Apr; 15(4 Pt 1):372-9.
Score: 0.008
-
Hypertension in the elderly: a review of the importance of systolic blood pressure elevation. J Clin Hypertens (Greenwich). 2002 Mar-Apr; 4(2):108-12, 119.
Score: 0.008
-
Halting the progression of heart failure: finding the optimal combination therapy. Cleve Clin J Med. 2002 Feb; 69(2):104-5, 109-10, 112.
Score: 0.008
-
Aspirin and angiotensin-converting enzyme inhibitors are safe when taken together after acute myocardial infarction in patients with left ventricular dysfunction. J Clin Hypertens (Greenwich). 2001 Nov-Dec; 3(6):376-7.
Score: 0.008
-
Hypertension 2001: pearls for the clinician. South Med J. 2001 Nov; 94(11):1054-7.
Score: 0.008
-
Uncontrolled Hypertension in an Elderly Man on Multiple Antihypertensive Drugs. Hypertension. 2020 12; 76(6):1658-1663.
Score: 0.007
-
Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association. Circulation. 2020 07 28; 142(4):e42-e63.
Score: 0.007
-
Combination agents as a means of improving adherence and other aspects of the sixth Joint National Committee Report. South Med J. 2000 May; 93(5):534-6.
Score: 0.007
-
Hypertension and Its Complications in a Young Man With Autoimmune Disease. Hypertension. 2017 04; 69(4):536-544.
Score: 0.006
-
Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. Hypertension. 2016 10; 68(4):888-95.
Score: 0.005
-
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
Score: 0.005
-
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med. 2014 Nov; 29(11):1475-83.
Score: 0.005
-
Renal sympathetic denervation for blood pressure control: a review of the current evidence and ongoing studies. J Clin Hypertens (Greenwich). 2014 May; 16(5):331-41.
Score: 0.005
-
Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT. Clin Nephrol. 2013 Oct; 80(4):235-48.
Score: 0.004
-
Analysis of recent papers in hypertension. Initial combination therapy provides more prompt blood pressure control and reduces cardiovascular events but remains underutilized. J Clin Hypertens (Greenwich). 2013 Aug; 15(8):523-5.
Score: 0.004
-
Increased calcium intake does not suppress circulating 1,25-dihydroxyvitamin D in normocalcemic patients with sarcoidosis. J Clin Invest. 1993 Apr; 91(4):1396-8.
Score: 0.004
-
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):20-31.
Score: 0.004
-
Highly interactive multi-session programs impact physician behavior on hypertension management: outcomes of a new CME model. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):97-105.
Score: 0.004
-
The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol. Am J Med. 2010 Jul; 123(7 Suppl 1):S2-8.
Score: 0.004
-
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29; 362(17):1575-85.
Score: 0.003
-
Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):42-50.
Score: 0.003
-
Does prehypertension represent an increased risk for incident hypertension and adverse cardiovascular outcome? Hypertension. 2009 Nov; 54(5):954-5.
Score: 0.003
-
Preliminary evaluation of phosphatidylethanol and alcohol consumption in patients with liver disease and hypertension. Alcohol Alcohol. 2009 Sep-Oct; 44(5):464-7.
Score: 0.003
-
Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009 Jul; 22(7):792-801.
Score: 0.003
-
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2008 Oct; 10(10):751-60.
Score: 0.003
-
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008 Sep; 52(3):412-24.
Score: 0.003
-
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2008 Jan 28; 168(2):207-17.
Score: 0.003
-
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun 18; 99(12A):44i-55i.
Score: 0.003
-
Cardiovascular risk factor control in communities--update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' Network. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):879-86.
Score: 0.003
-
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep; 48(3):374-84.
Score: 0.003
-
A trial of education, prompts, and opinion leaders to improve prescription of lipid modifying therapy by primary care physicians for patients with ischemic heart disease. Qual Saf Health Care. 2005 Aug; 14(4):258-63.
Score: 0.003
-
Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich). 2005 Jul; 7(7):409-16.
Score: 0.003
-
Excessive alcohol consumption and hypertension: clinical implications of current research. J Clin Hypertens (Greenwich). 2005 Jun; 7(6):346-51.
Score: 0.002
-
Hypertension and heart failure. Roundtable discussion. J Clin Hypertens (Greenwich). 2004 Jun; 6(6):326-32.
Score: 0.002
-
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004 Mar; 6(3):116-25.
Score: 0.002
-
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2001 Apr; 24(4):654-8.
Score: 0.002
-
Stability of basal metabolic rate over selected days of the menstrual cycle. Obes Res. 1995 May; 3(3):301-2.
Score: 0.001